Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
The future of allogeneic hematopoietic stem cell transplantation: minimizing pain, maximizing gain
Marie-Térèse Little, Rainer Storb
Marie-Térèse Little, Rainer Storb
Published June 15, 2000
Citation Information: J Clin Invest. 2000;105(12):1679-1681. https://doi.org/10.1172/JCI10375.
View: Text | PDF
Commentary

The future of allogeneic hematopoietic stem cell transplantation: minimizing pain, maximizing gain

  • Text
  • PDF
Abstract

Authors

Marie-Térèse Little, Rainer Storb

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Schematic illustration of nonmyeloablative HSCT-induced mixed donor-host...
Schematic illustration of nonmyeloablative HSCT-induced mixed donor-host chimerism. Successful transplantation generally requires some level of host immunosuppression, except in cases of T-cell deficiency. This has often involved harsh TBI, but there is great interest in reducing the dosage to low, easily tolerated levels, such as the 200 cGy shown here, or even replacing this step entirely with other forms of conditioning. This process leads first to a state of mixed chimerism, in which both donor and recipient cells are detectable in the subject’s lymphoid and myeloid compartments and thymus. To correct recessive genetic diseases, this state of mixed chimerism may suffice, whereas other conditions, such as malignancy and autoimmune disease, may require the complete replacement of host cells with donor cells. Such a state of all-donor chimerism can be initiated either in a spontaneous episode of graft-versus-host disease or through an infusion of donor lymphocytes.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts